Albany Molecular Research Inc. (NASDAQ:AMRI)’s share price was up 4.9% during mid-day trading on Wednesday . The stock traded as high as $14.46 and last traded at $14.39, with a volume of 115,179 shares changing hands. The stock had previously closed at $13.72.

Separately, Morgan Stanley restated a “buy” rating on shares of Albany Molecular Research in a report on Sunday, May 8th.

The firm’s 50 day moving average is $14.01 and its 200-day moving average is $14.86. The company’s market capitalization is $503.24 million.

Albany Molecular Research (NASDAQ:AMRI) last issued its quarterly earnings results on Tuesday, May 10th. The company reported $0.07 EPS for the quarter, missing the Zacks’ consensus estimate of $0.21 by $0.14. The firm had revenue of $102.80 million for the quarter, compared to analysts’ expectations of $107.20 million. On average, analysts predict that Albany Molecular Research Inc. will post $1.05 EPS for the current year.

In other news, Director Kevin Oconnor sold 5,000 shares of the stock in a transaction on Tuesday, May 31st. The shares were sold at an average price of $14.41, for a total value of $72,050.00. Following the transaction, the director now owns 52,955 shares of the company’s stock, valued at approximately $763,081.55. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, COO George Svokos purchased 12,500 shares of the firm’s stock in a transaction dated Friday, May 13th. The stock was bought at an average cost of $12.82 per share, for a total transaction of $160,250.00. Following the acquisition, the chief operating officer now directly owns 108,685 shares in the company, valued at $1,393,341.70. The disclosure for this purchase can be found here.

An institutional investor recently raised its position in Albany Molecular Research stock. Mutual of America Capital Management LLC raised its stake in shares of Albany Molecular Research Inc. (NASDAQ:AMRI) by 5.8% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 158,399 shares of the company’s stock after buying an additional 8,689 shares during the period. Mutual of America Capital Management LLC owned 0.46% of Albany Molecular Research worth $3,144,000 at the end of the most recent quarter.

Albany Molecular Research, Inc is a global contract research and manufacturing company. The Company provides drug discovery, development, and manufacturing services. The Company operates through three segments: Discovery and Development Services (DDS), Active Pharmaceutical Ingredients (API) and Drug Product Manufacturing (DPM).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.